BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Dear Doctor Letter (Rote-Hand-Brief) on REGRANEX®: Extension of existing contraindications

2010.03.15

Active substance: becaplermin

REGRANEX® (active substance: becaplermin) contraindicated for patients with malign diseases.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 79KB, File is accessible